5. Conclusions
The UGT1A1*6 andUGT1A1*28 genetic polymorphisms especially when patients carried
homozygous of these variants were significantly associated with
irinotecan induced severe toxicities such as neutropenia and diarrhea in
Asian cancer patients. The findings of this analysis suggest that both
of the UGT1A1*6 and *28 genetic variants should screen in
Asian cancer patients to reduce irinotecan toxicities substantially.
Also, suggested to avoid high
doses of irinotecan (>150mg/m2) to reduce
toxicities significantly. It is high time to prepare national guidelines
for adhering routine preemptive screening of UGT1A1*6 andUGT1A1*28 variants in cancer patients before prescribing
irinotecan. This may facilitate rapid translation of UGT1A1*6 andUGT1A1*28 pharmacogenomics into the clinical practice in the form
of precision irinotecan therapy.
Supplementary Materials: Supplementary Table 1: Quality
assessment of the included studies by Newcastle Ottawa Scale (NOS).
Author Contributions:Conceptualization, CS, CA and MB;
Data curation CA, NV, YH and NN; Formal analysis; MB, SS and NV;
Methodology, CS, CA, NV and MB; Project administration, PJ and JR;
Supervision, CS; Writing—original draft, CA, MB, NV and CS. The final
manuscript was revised by all authors, and this version was approved to
be published.
Funding: This study was
supported by grants from the (1) Mahidol University International
Postdoctoral Fellowship, Mahidol University (2) Faculty of Medicine,
Ramathibodi Hospital, Mahidol University (3) the Health System Research
Institute under Genomics Thailand Strategic Fund, (4) The International
Research Network-The Thailand Research Fund (IRN60W003).
Institutional Review Board Statement: Not applicable since it
was a meta-analysis.
Informed Consent Statement: Not applicable
Data Availability Statement:This manuscript does not contain
any associated data. However, the raw data supporting the findings of
this study is freely available upon reasonable request.
Acknowledgments: The authors thank the staffs of
Pharmacogenomic and Personalized Medicine of Ramathibodi Hospital.
Conflicts of Interest: The authors declare that they have no
conflicts of interest.